046. COVID-19: Special Populations: Thursday, 12:15 - 1:30 p.m.
Poster Session: COVID-19: Special Populations
Ghady Haidar, MD (he/him/his)
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Justin Ludwig, MA
Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Donald M. Yealy, MD
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Haley Camacho, PharmD candidate
Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Tina Chinakarn, MPH
Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Kevin Kip, PhD, FAAAS, FAHA
UPMC Health Services Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Stephen Koscumb, BA, BS
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Oscar Marroquin, MD, MS
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Tami Minnier, MSN, RN
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Graham M. Snyder, MD, SM (he/him/his)
Medical Director, Infection Prevention and Hospital Epidemiology
University of Pittsburgh
Pittsburgh, PA, United States
Chelsea Woodworth, MS, RN, RHIA
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Cátia Ferreira, PhD
Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA
Wilmington, Delaware, United States
Lisa Glasser, MD
Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA
Wilmington, Delaware, United States
Kathleen Heil, RN, BSN
Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA
Wilmington, Delaware, United States
Andrew Lee, MSc
Medical and Payor Statistics, BioPharmaceutical Business Unit, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
Carla Talarico, PhD, MPH
Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
Sudhir Venkatesan, MPH, PhD
Medical and Payer Evidence Statistics, BioPharmaceutical Medical, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
Sylvia Taylor, PhD, MPH, MBA
Medical Evidence, Vaccines and Immune Therapies Unit, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
Erin K. McCreary, PharmD (she/her/hers)
Director of Infectious Diseases Improvement and Clinical Research Innovation
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
John W. Mellors, MD
Chief
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States